C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/12 (2006.01) A61K 31/7088 (2006.01) A61K 38/08 (2006.01) A61K 39/395 (2006.01) A61K 48/00 (2006.01) A61P 35/00 (2006.01) C07K 7/02 (2006.01) C07K 7/06 (2006.01) C07K 14/47 (2006.01) C07K 14/705 (2006.01) C07K 14/725 (2006.01) C07K 14/82 (2006.01) C07K 16/18 (2006.01) C12N 15/11 (2006.01) C12P 21/08 (2006.01) C12Q 1/68 (2006.01) G01N 33/53 (2006.01) A61K 38/00 (2006.01) A61K 39/00 (2006.01)
Patent
CA 2445018
The invention relates to a universal tumour-associated oligopeptide, which is recognised by CD8-positive cytotoxic T-lymphocytes (CTL) as a peptide antigen and which causes a CTL-induced lysis and/or apoptosis of tumour or leukaemia cells. The oligopeptide has the amino acid sequence LLGDLFGV, which corresponds to the amino acid positions 81 to 88 of the hdm2 proto- oncoprotein, or an amino acid sequence that can be derived from said sequence, which constitutes the functional equivalent of the amino acid sequence LLGDLFGV. Said oligopeptide constitutes an epitope for CD8-positive CTLs and is suitable for inducing a restricted immune response of CD8-positive CTLs to the human leukocyte antigen of the molecular group MHC class I, allelomorph variant A2, against tumour and leukaemia cells.
L'invention concerne un oligopeptide universel associé aux tumeurs, reconnu en tant qu'antigène peptidique par des lymphocytes T cytotoxiques CD8-positifs (ZTL), et provoquant une lyse et/ou une apoptose de cellules tumorales ou leucémiques induite par ZTL. Ledit oligopeptide présente la séquence d'acides aminés LLGDLFGV correspondant aux positions 81 à 88 des acides aminés de la proto-oncoprotéine hdm2, ou une séquence d'acides aminés dérivée représentant un équivalent fonctionnel de la séquence d'acides aminés LLGDLFGV. Ledit oligopeptide représente un épitope de ZTL CD8-positifs, et peut provoquer une réponse immunitaire restreinte à l'antigène de leucocytes humain du groupe moléculaire <= MHC classe I >=, allélomorphe A2, de ZTL CD8-positifs contre des cellules tumorales et leucémiques.
Stanislawski Thomas
Theobald Matthias
Ganymed Pharmaceuticals Ag
Immugenics Ag
Smart & Biggar
LandOfFree
Tumour peptide antigen produced from human mdm2 proto-oncogene does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumour peptide antigen produced from human mdm2 proto-oncogene, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumour peptide antigen produced from human mdm2 proto-oncogene will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1974422